ライフサイエンスコーパス: hematopoietic tumor

1 ted equivalent immunity against A20 and P815 hematopoietic tumors.

2 ontaneous aneuploidy and a predisposition to hematopoietic tumors.

3 tment to the bone marrow, a key location for hematopoietic tumors.

4 the highly sensitive and readily accessible hematopoietic tumors.

5 X-5461 is being tested in relapse/refractory hematopoietic tumors.

6 helial carcinomas, soft tissue sarcomas, and hematopoietic tumors.

7 g pathway play an important role in lymphoid/hematopoietic tumors.

8 elial cancers, but has not been described in hematopoietic tumors.

9 in the cell lines derived from solid as from hematopoietic tumors.

10 earrangements are found in a large number of hematopoietic tumors.

11 tatic tumor growth in a variety of solid and hematopoietic tumors.

12 oader uses of retinoids in the management of hematopoietic tumors are discussed.

13 pectral karyotypic analysis that MYC-induced hematopoietic tumors are highly genetically complex and

14 chemotherapy for the treatment of solid and hematopoietic tumors are underway.

15 also been observed in a variety of solid and hematopoietic tumors at low frequency.

16 three genes are almost universal in lymphoid/hematopoietic tumors but the patterns of gene methylated

17 Mutation analysis of hematopoietic tumor cell lines and B-CLL tumor samples r

18 In some hematopoietic tumor cell lines having altered c-myc gene

19 d by multiple genotoxic stress agents in all hematopoietic tumor cell lines we have examined.

20 ion of mRNA and protein for VEGF in 12 human hematopoietic tumor cell lines, representing multiple li

21 In hematopoietic tumor cell lines, the association of p18-c

22 f TME-mediated drug resistance that protects hematopoietic tumor cells from the initial effect of div

23 Earlier we showed that in hematopoietic tumor cells, caspase-mediated cleavage of

24 eavage of Cyclin E generates p18-Cyclin E in hematopoietic tumor cells.

25 ent proteolysis of cyclin E for apoptosis of hematopoietic tumor cells.

26 tions reveal that Cdk4 and Cdk6 cooperate in hematopoietic tumor development and suggest a role for C

27 , or DNA agarose gels in xenografts of human hematopoietic tumors HL-60, SUDHL-4, and Nalm/6.

28 d, or constitutively activated in many human hematopoietic tumors; however, the molecular mechanisms

29 Hematopoietic tumors in both humans and mice frequently

30 sufficient to induce sustained regression of hematopoietic tumors in transgenic mice, except in tumor

31 ene is aberrantly methylated in 86% of human hematopoietic tumors, including 8 of 9 pediatric acute l

32 Whereas H-Ras(G12V) elicited papillomas and hematopoietic tumors, K-Ras(G12V) induced lung tumors an

33 We show here in a Drosophila melanogaster hematopoietic tumor model, however, that JAK overactivat

34 ccine approach was assessed in several other hematopoietic tumor models and was also therapeutically

35 Solid and hematopoietic tumors often experience genomic instabilit

36 We examined 150 lymphoid/hematopoietic tumors or potential premalignant specimens

37 Retroviral insertional mutagenesis in mouse hematopoietic tumors provides a potent cancer gene disco

38 Retroviral insertional mutagenesis in mouse hematopoietic tumors provides a powerful cancer gene dis

39 Analysis of 63 hematopoietic tumors revealed that PiggyBac is capable o

40 Our data suggest that PHF6 is a hematopoietic tumor suppressor and is important for fine

41 ubiquitin ligase Fbw7, a recently identified hematopoietic tumor suppressor that can target for degra

42 sm leading to inactivation of this important hematopoietic tumor suppressor.

43 itutive activation of Rel/NF-kappaB in human hematopoietic tumors, the v-Rel oncoprotein induces aggr

44 because bfl-1 is up-regulated in many human hematopoietic tumors, this finding suggests that strateg

45 Furthermore, a host of solid and hematopoietic tumor types exhibit constitutive activatio